Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

which is related to the change in fair value of the liability for contingent consideration in connection with the acquisition of Proteolix; such exclusion facilitates comparisons of Onyx's operating results to peer companies.Employee stock-based compensation: The effects of employee stock-based compensation are excluded because of varying available valuation methodologies, subjective assumptions and the variety of award types; such exclusion facilitates comparisons of Onyx's operating results to peer companies.Imputed interest related to the convertible senior notes due 2016: The effects of imputed interest related to the convertible senior notes due 2016 are excluded because this expense is non-cash; such exclusion facilitates comparisons of Onyx's cash operating results to peer companies.Advance funding to S*BIO and impairment of equity investment in S*BIO: The effects of the termination of the S*BIO collaboration agreement are excluded because they do not relate to the normal and recurring transactions of Onyx's business; such exclusion allows for a better representation of the ongoing economics of the business, facilitates comparison to peer companies and is reflective of how Onyx management internally manages the business.(6) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded from non-GAAP diluted per share amounts for the three months ended March 31, 2011 and 2010 because their effect would be anti-dilutive.ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)March 31,December 31,20112010(unaudited)(7)AssetsCash, cash equivalents and current marketable securities

$
533,389$
549,313Other current assets

68,82895,871Total current assets

602,217645,184Marketable securities, non-current

28,29328,555Property and equipment, net

18,57710,822Intangible assets - in-process research and
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim today ... (FDA) accepted for review the New Drug Application ... and olodaterol delivered via the Respimat ® ... maintenance treatment of airflow obstruction in patients with ... and/or emphysema. Tiotropium + olodaterol FDC will not ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Leaving the car ... public transit is good for your health, a new study ... United Kingdom and found that 76 percent of men and ... men and 11 percent of women used public transit, and ... or walked. Those who drove to work weighed more ...
(Date:8/20/2014)... According to a new market ... SPD, Liquid Crystal, Microblinds, Thermographic and Photochromics), by ... others), by geography - Global Forecast to 2014 ... Smart glass market was worth $1581.4 Million in ... by 2020, at an estimated CAGR of 20% ...
(Date:8/20/2014)... Raleigh, NC (PRWEB) August 20, 2014 Doctors ... a way to wipe out mesothelioma in laboratory mice by ... Mesothelioma has just posted details of the study on its ... , Scientists with Hong Kong University’s AIDS Institute of ... death protein 1” or PD-1. By altering DNA, the vaccine ...
(Date:8/20/2014)... New Jersey’s Medical Marijuana Program has ... tens of thousands of patients in the state. However, ... that would expand the list of qualifying conditions and ... summer by State Assemblywoman Linda Stender, the need to ... growing. , To help fill the information gap for ...
(Date:8/20/2014)... OR (PRWEB) August 20, 2014 August ... are urged to become educated about eye health and ... examined. One frequently overlooked eye condition that must be ... Sharon Kleyne Hour Power of Water radio show, is ... children increasing exponentially, childhood dry eye is becoming a ...
Breaking Medicine News(10 mins):Health News:Want to Stay Slim? Leave the Car at Home 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 2Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 3Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 4Health News:Smart Glass Market by Technology Worth $5814 Million by 2020 – New Report by MarketsandMarkets 5Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3
... painkillers to treat inflammation are linked to an increased ... or flutter), concludes a study published on bmj.com ... drugs (NSAIDS) as well as new generation anti-inflammatory drugs, ... already been linked to an increased risk of heart ...
... Dennis Thompson HealthDay Reporter , SUNDAY, July 3 (HealthDay ... the summer air with dazzling colors and deafening sounds. But they ... year are harmed by fireworks, many of them maimed for life, ... care. "Where we see injuries is a lack of common ...
... N.C. July 4, 2011 Smoking cigarettes is a ... the smokers who choose to use one of the most ... the risk of serious cardiovascular events are on their way. ... Baptist Medical Center, in collaboration with researchers at Johns Hopkins ...
... Reinberg HealthDay Reporter , FRIDAY, July 1 (HealthDay ... are endorsing a U.S. health advisory panel,s recommendation that the ... breast cancer. The reason: There,s still a lack of ... Avastin was given fast-track approval by the U.S. ...
... The children most likely to walk or cycle to ... in an economically disadvantaged home, according to survey results that ... Pabayo of the University of Montreal Hospital Research Centre and ... is unique in that it follows the same group of ...
... the international aid community started to fund health programs ... support for tackling infectious diseases, and for implementing immunization ... and by governments are not always the same. New ... Globalization and Health uses ,agency theory, to examine ...
Cached Medicine News:Health News:Common painkillers linked to irregular heart rhythm 2Health News:Safety Experts Warn of Fireworks Dangers 2Health News:Safety Experts Warn of Fireworks Dangers 3Health News:Safety Experts Warn of Fireworks Dangers 4Health News:Chantix associated with 72 percent increased risk of serious CV events 2Health News: Avastin Rejection Supported by Cancer Experts 2Health News: Avastin Rejection Supported by Cancer Experts 3Health News: Avastin Rejection Supported by Cancer Experts 4Health News:Urban children are healthier commuters than rural teens 2Health News:Getting aid to where it is needed 2
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Graft Workstation offers the surgeon flexibility in graft preparation. The posts are interchangeable and the system adapts to both soft tissue and bone grafts selection. Sizing gauges off...
... Medicine Knot Pusher is a reusable instrument used ... Knot Pusher is utilized in the handling and ... two piece shaft allows the surgeon to place ... pushing. The ring handle allows the surgeon ease ...
Medicine Products: